Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/bjc.2014.156 http://scihub22266oqcxt.onion/10.1038/bjc.2014.156 C3992506!3992506!24667651     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Cancer 2014 ; 110 (8): 1950-7 Nephropedia Template TP {{tp|p=24667651|t=2014. Adaptive designs for clinical trials assessing biomarker-guided treatment strategies |pdf=|usr=}}{{24667651}} gab.com Text Adaptive designs for clinical trials assessing biomarker-guided treatment strategies JO: Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=24667651 #FOAvip Background:: The Biomarker Strategy Design has been proposed for trials assessing the value of a biomarker in guiding treatment in oncology. In such trials, patients are randomised to either receive the standard chemotherapy treatment or a biomarker-directed treatment arm, in which biomarker status is used to guide treatment. Methods:: Motivated by a current trial, we consider an adaptive design in which two biomarkers are assessed. The trial is conducted in two stages. In the first stage, patients in the biomarker-guided arm are assessed using a standard and an alternative cheaper biomarker, with the standard biomarker guiding treatment. An analysis comparing biomarker results is then used to choose the biomarker to use for the remainder of the trial. The new biomarker is used if the results for the two biomarkers are sufficiently similar. Results:: We show that in practical situations the first-stage results can be used to adapt the trial without type I error rate inflation. We also show that there can be considerable cost gains with only a small loss in power in the case where the alternative biomarker is highly concordant with the standard one. Conclusions:: Adaptive designs have an important role in reducing the cost and increasing the clinical utility of trials evaluating biomarker-guided treatment strategies. Twit Text FOAVip Adaptive designs for clinical trials assessing biomarker-guided treatment strategies ????Br J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=24667651 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24667651 #FOAvip English Wikipedia <ref>{{Cite pmid|24667651}}</ref> Adaptive designs for clinical trials assessing biomarker-guided treatment strategies #MMPMID24667651 Wason J; Marshall A; Dunn J; Stein RC; Stallard N Br J Cancer 2014[Apr]; 110 (8): 1950-7 PMID24667651show ga Background:: The Biomarker Strategy Design has been proposed for trials assessing the value of a biomarker in guiding treatment in oncology. In such trials, patients are randomised to either receive the standard chemotherapy treatment or a biomarker-directed treatment arm, in which biomarker status is used to guide treatment. Methods:: Motivated by a current trial, we consider an adaptive design in which two biomarkers are assessed. The trial is conducted in two stages. In the first stage, patients in the biomarker-guided arm are assessed using a standard and an alternative cheaper biomarker, with the standard biomarker guiding treatment. An analysis comparing biomarker results is then used to choose the biomarker to use for the remainder of the trial. The new biomarker is used if the results for the two biomarkers are sufficiently similar. Results:: We show that in practical situations the first-stage results can be used to adapt the trial without type I error rate inflation. We also show that there can be considerable cost gains with only a small loss in power in the case where the alternative biomarker is highly concordant with the standard one. Conclusions:: Adaptive designs have an important role in reducing the cost and increasing the clinical utility of trials evaluating biomarker-guided treatment strategies. äAdaptive designs for clinical trials assessing biomarker-guided treatm(epmc).pdf DeepDyve Pubget Overpricing